Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03830008
Other study ID # BASEC-2017-01175
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 21, 2018
Est. completion date March 20, 2020

Study information

Verified date February 2021
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current refugee crisis across the Middle East and Europe has large effects on individual refugees' psychological well-being, as well as on the healthcare systems of countries hosting refugees. For example, in Switzerland patients sometimes have to wait up to 12 months for the specific psychological treatment due to a lack of specialists. To address this problem the WHO has developed Problem Management Plus (PM+), a brief (five sessions), low-intensity psychological intervention, delivered by paraprofessionals, that addresses common mental disorders in people in communities affected by adversity. The feasibility of PM+ has never been examined in Switzerland before, this is the aim of the current pilot study.


Description:

Recent crises in the Middle East, most notably in Syria, have resulted in an unprecedented increase in the worldwide number of refugees and asylum seekers. Switzerland (CH) is strongly affected by this crisis too. Eight percent of asylum requests in 2016 were made by people from Syria (2015: 12 %). More than 7'000 asylum seekers from Syria entered CH over the last two years. Due to the ongoing war in this region, it is unlikely that this kind of migration and flight will stop. Notably, 50% of the refugee population are children and adolescents. Refugees have typically been exposed to multiple stressors related to war and displacement including loss of family members, destruction of homes and livelihoods and human rights violations such as sexual violence or torture. They have often undertaken a risky and stressful flight leaving their homes for an unknown future. Accordingly, studies consistently show that refugees are at considerable risk of developing common mental disorders, including depression, anxiety, posttraumatic stress disorder (PTSD) and related somatic health symptoms. Recent WHO projections suggest that approximately 15-20% of Syrian refugees will develop some type of mental health problem and therefore represent an enormous public mental health challenge. According to the UNHCR, 86% of all displaced persons remain in conflict or neighboring countries where appropriate health care is mostly not available. But also Western health systems are often unable to appropriately cover the needs of this particularly vulnerable population regarding prevention and treatment of mental health problems. As a response to this situation, the WHO developed the low-intensity Problem Management Plus (PM+) programs, a new generation of shorter, less expensive and trans-diagnostic (i.e., not specifically aimed at treating a certain mental disorder) programs to reduce common mental health symptoms and improve psychosocial functioning. PM+ is based on the WHO treatment guidelines for conditions related to stress. PM+ is a 5-sessions intervention aimed at reducing symptoms of depression, anxiety, PTSD, and related conditions, is delivered by trained non-specialized workers or lay people, and is available in individual and group delivery formats for both children and adults. It comprises evidence-based techniques of (a) problem solving, (b) stress management, (c) behavioral activation, and (d) accessing social support. PM+ has been successfully implemented in Kenya and Pakistan. The STRENGTHS (Syrian REfuGees MeNTal HealTH Care Systems) study aims at evaluating the effectiveness and implementation of PM+ with Syrian refugees in different settings in low- and high-resource countries. The study consortium includes international experts in the domains of trauma and public mental health as well as representatives of WHO and UNHCR. The Zürich study site has been consigned to examine PM+ with adult refugees in an individual treatment setting in Switzerland. At the same time, similar studies in other countries will be undertaken. Despite the objective of these studies to implement and evaluate the effectiveness of PM+ in refugees, each research institution acts independently. Moreover, the other studies will be completed in different treatment settings - i.e., in children and adolescents (Lebanon), in groups (Turkey and Netherlands), and internet-delivered PM+ (Germany and Egypt). To date, the feasibility of PM+ has not been investigated in a highly industrialized country, such as Switzerland. In the present study, the investigators will evaluate the feasibility of PM+ in Syrian refugees in Switzerland. This research entails single-blind randomized controlled trial. The amendment was secured by December 2018. Trainers, assessors, supervisors and helpers are already identified, recruited an trained. After the approval, the first participants will be identified, invited to screening and if they fulfill the criteria they will be invited to participate in the pilot study. The pilot study will end by the end of 2019. After the pilot study the results will be evaluated, analyzed and integrated in the planning of the definitive randomized controlled trial (RCT) (next study, not the part of current registration).


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date March 20, 2020
Est. primary completion date March 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male and female Syrian refugees or asylum seekers who entered Switzerland after the beginning of Syrian Civil War in March 2011 - = 18 years of age - Arabic-speaking - Signed Informed Consent after being informed - Increased psychological distress (K10 > 15) - Reduced psychological functioning (WHODAS 2.0 > 16) Exclusion Criteria: - Inability to follow the procedures of the study - Previous enrolment into the current study - Previous or currently enrolment of a family member into the current study - Participants under tutelage - Acute or severe psychiatric (e.g. schizophrenia) or neurological illness (e.g. dementia) - Imminent suicide risk

Study Design


Intervention

Behavioral:
Problem Management Plus
PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.

Locations

Country Name City State
Switzerland University Hospital Zurich Zürich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

References & Publications (11)

Dawson KS, Bryant RA, Harper M, Kuowei Tay A, Rahman A, Schafer A, van Ommeren M. Problem Management Plus (PM+): a WHO transdiagnostic psychological intervention for common mental health problems. World Psychiatry. 2015 Oct;14(3):354-7. doi: 10.1002/wps.20255. — View Citation

Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, van Ommeren M, Yasamy MT, Ayuso-Mateos JL, Birbeck GL, Drummond C, Freeman M, Giannakopoulos P, Levav I, Obot IS, Omigbodun O, Patel V, Phillips M, Prince M, Rahimi-Movaghar A, Rahman A, Sander JW, Saunders JB, Servili C, Rangaswamy T, Unützer J, Ventevogel P, Vijayakumar L, Thornicroft G, Saxena S. Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. PLoS Med. 2011 Nov;8(11):e1001122. doi: 10.1371/journal.pmed.1001122. Epub 2011 Nov 15. — View Citation

Guidelines for the Management of Conditions Specifically Related to Stress. Geneva: World Health Organization; 2013. — View Citation

Hassan, G., Kirmayer, L. J., Mekki-Berrada, A., Quosh, C., el Chammay, R., Deville-Stoetzel, J., . . . Coutts, A. (2015). Culture, context and the mental health and psychosocial wellbeing of Syrians: a review for mental health and psychosocial support staff working with Syrians affected by armed conflict. Geneva: UNHCR.

mhGAP Intervention Guide for Mental, Neurological and Substance Use Disorders in Non-Specialized Health Settings: Mental Health Gap Action Programme (mhGAP): Version 2.0. Geneva: World Health Organization; 2016. — View Citation

Mollica RF, Caspi-Yavin Y, Bollini P, Truong T, Tor S, Lavelle J. The Harvard Trauma Questionnaire. Validating a cross-cultural instrument for measuring torture, trauma, and posttraumatic stress disorder in Indochinese refugees. J Nerv Ment Dis. 1992 Feb;180(2):111-6. — View Citation

Rahman A, Riaz N, Dawson KS, Usman Hamdani S, Chiumento A, Sijbrandij M, Minhas F, Bryant RA, Saeed K, van Ommeren M, Farooq S. Problem Management Plus (PM+): pilot trial of a WHO transdiagnostic psychological intervention in conflict-affected Pakistan. World Psychiatry. 2016 Jun;15(2):182-3. doi: 10.1002/wps.20312. — View Citation

Sijbrandij M, Acarturk C, Bird M, Bryant RA, Burchert S, Carswell K, de Jong J, Dinesen C, Dawson KS, El Chammay R, van Ittersum L, Jordans M, Knaevelsrud C, McDaid D, Miller K, Morina N, Park AL, Roberts B, van Son Y, Sondorp E, Pfaltz MC, Ruttenberg L, Schick M, Schnyder U, van Ommeren M, Ventevogel P, Weissbecker I, Weitz E, Wiedemann N, Whitney C, Cuijpers P. Strengthening mental health care systems for Syrian refugees in Europe and the Middle East: integrating scalable psychological interventions in eight countries. Eur J Psychotraumatol. 2017 Nov 7;8(sup2):1388102. doi: 10.1080/20008198.2017.1388102. eCollection 2017. Review. — View Citation

Steel Z, Chey T, Silove D, Marnane C, Bryant RA, van Ommeren M. Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. JAMA. 2009 Aug 5;302(5):537-49. doi: 10.1001/jama.2009.1132. Review. — View Citation

Tol WA, Barbui C, van Ommeren M. Management of acute stress, PTSD, and bereavement: WHO recommendations. JAMA. 2013 Aug 7;310(5):477-8. doi: 10.1001/jama.2013.166723. — View Citation

Weathers, F. W., Litz, B. T., Keane, T. M., Palmieri, P., Marx, B., & Schnurr, P. (2013). The ptsd checklist for dsm-5 (pcl-5). Scale available from the National Center for PTSD at www.ptsd.va.gov.

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Verification procedure to the measurement of change in response to therapy at baseline patient-generated outcome measure by the Psychological Outcomes Profiles (PSYCHLOPS) scale [PSYCHLOPS has questions on Problems, Function and Wellbeing. Participants are asked to describe their main Problem or Problems and how this affects them (Function). Responses to all questions are scored [likert-scale 0 to 5 from "severely affected" to "not at all affected"); it is a highly sensitive measure of change during the course of psychotherapeutic interventions.] baseline assessment (before PM+)
Other Verification procedure to the measurement of change in response to therapy at post-assessment patient-generated outcome measure by the Psychological Outcomes Profiles (PSYCHLOPS) scale [PSYCHLOPS has questions on Problems, Function and Wellbeing. Participants are asked to describe their main Problem or Problems and how this affects them (Function). Responses to all questions are scored [likert-scale 0 to 5 from "severely affected" to "not at all affected"); it is a highly sensitive measure of change during the course of psychotherapeutic interventions.] post-assessment baseline (after PM+/ETAU)
Other Verification procedure to the measurement of change in response to therapy 3 months after patient-generated outcome measure by the Psychological Outcomes Profiles (PSYCHLOPS) scale [PSYCHLOPS has questions on Problems, Function and Wellbeing. Participants are asked to describe their main Problem or Problems and how this affects them (Function). Responses to all questions are scored [likert-scale 0 to 5 from "severely affected" to "not at all affected"); it is a highly sensitive measure of change during the course of psychotherapeutic interventions.] 3-months follow-up (after PM+/ETAU)
Other Post-migration stressors at baseline will be assessed using a version of the Post-Migration Living Difficulties Checklist (PMLDC) baseline assessment (before PM+)
Other Post-migration stressors at post-assessment will be assessed using a version of the Post-Migration Living Difficulties Checklist (PMLDC) post-assessment baseline (after PM+/ETAU)
Other Post-migration stressors 3 months after will be assessed using a version of the Post-Migration Living Difficulties Checklist (PMLDC) 3-months follow-up (after PM+/ETAU)
Other Previous exposure to traumatic events assessed using the Traumatic Events (TE) - a combination of two standardized questionnaires, namely the Life Events Checklist (LEC) (Weathers et al., 2013) and the Harvard Trauma Questionnaire (HTQ) (Mollica et al., 1992). HTQ consists of 3 sections with 48 questions. LEC consists of 17 question. Single questions from HTQ (Section 1) and LEC are summarized to the sequence of 27 questions (about experienced trauma or adversities with yes/no answer format). The number of positive answers is the outcome value. baseline
Other Access to Health Care Services (AHCS) The set of question regarding previous contact with the mental health care services and the previous experiences regarding the utilization of any forms of mental support baseline assessment (before PM+)
Other Medical service utilization of people with mental disorders at baseline accessed using the Client Service Receipt Inventory (CSRI) as the basis for calculating the costs of care for mental health cost-effectiveness research baseline assessment (before PM+)
Other Medical service utilization of people with mental disorders at post-assessment accessed using the Client Service Receipt Inventory (CSRI) as the basis for calculating the costs of care for mental health cost-effectiveness research post-assessment baseline (after PM+/ETAU)
Other Medical service utilization of people with mental disorders at post-assessment 3 months after accessed using the Client Service Receipt Inventory (CSRI) as the basis for calculating the costs of care for mental health cost-effectiveness research 3-months follow-up (after PM+/ETAU)
Primary Verification procedure to the measurement in psychological distress at baseline assessment measured by the Hopkins Symptom Checklist (HSCL-25) baseline assessment (before PM+)
Primary Verification procedure to the measurement in psychological distress after PM+ intervention or ETAU measured by the Hopkins Symptom Checklist (HSCL-25) post-assessment baseline (after PM+/ETAU)
Primary Verification procedure to the measurement in psychological distress 3 months after PM+ intervention or ETAU measured by the Hopkins Symptom Checklist (HSCL-25) 3-months follow-up (after PM+/ETAU)
Secondary Verification procedure to the measurement of symptoms of posttraumatic stress disorder at baseline assessment measured using the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (PCL-5) baseline assessment (before PM+)
Secondary Verification procedure to the measurement of symptoms of posttraumatic stress disorder after PM+ intervention or ETAU measured using the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (PCL-5) post-assessment baseline (after PM+/ETAU)
Secondary Verification procedure to the measurement of symptoms of posttraumatic stress disorder 3 months after PM+ intervention or ETAU measured using the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (PCL-5) 3-months follow-up (after PM+/ETAU)
Secondary Verification procedure to the measurement of functional disability at screening assessed by the WHODAS 2.0 (WHO Disability Assessment Schedule 2.0) screening (before PM+)
Secondary Verification procedure to the measurement of functional disability after PM+ intervention or ETAU assessed by the WHODAS 2.0 (WHO Disability Assessment Schedule 2.0) post-assessment baseline (after PM+/ETAU)
Secondary Verification procedure to the measurement of functional disability 3 months after PM+ intervention or ETAU assessed by the WHODAS 2.0 (WHO Disability Assessment Schedule 2.0) 3-months follow-up (after PM+/ETAU)
Secondary Feasibility of PM+ by the number of dropouts Monitoring of the dropouts by number of patients screening (before PM+)
Secondary Feasibility of PM+ by the number of dropouts Monitoring of the dropouts by number of patients baseline assessment (before PM+)
Secondary Feasibility of PM+ by the number of dropouts Monitoring of the dropouts by number of patients post-assessment baseline (after PM+/ETAU)
Secondary Feasibility of PM+ by the number of dropouts Monitoring of the dropouts by number of patients 3-months follow-up (after PM+/ETAU)
Secondary Feasibility of PM+ by feedbacks regarding the understanding of intervention and measurements instruments Monitoring of wrong understanding or wrong translation (by number of patients and the scope of the feedback) screening (before PM+)
Secondary Feasibility of PM+ by feedbacks regarding the understanding of intervention and measurements instruments Monitoring of wrong understanding or wrong translation (by number of patients and the scope of the feedback) baseline assessment (before PM+)
Secondary Feasibility of PM+ by feedbacks regarding the understanding of intervention and measurements instruments Monitoring of wrong understanding or wrong translation (by number of patients and the scope of the feedback) post-assessment baseline (after PM+/ETAU)
Secondary Feasibility of PM+ by feedbacks regarding the understanding of intervention and measurements instruments Monitoring of wrong understanding or wrong translation (by number of patients and the scope of the feedback) 3-months follow-up (after PM+/ETAU)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A